SCHEMBL19645707

SCHEMBL19645707

COc1cc2c(Cl)c(C)cnc2cc1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.53
PDGFRA P16234 1/20 0.53
PDPK1 O15530 2/20 0.50
KDM1A O60341 1/20 0.50
IRAK1 P51617 1/20 0.49
IRAK4 Q9NWZ3 1/20 0.49
KIT P10721 1/20 0.48
EGFR P00533 8/20 0.48
ELANE P08246 1/20 0.48
CTSV O60911 1/20 0.48
CTSL P07711 1/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
KDR P35968 2/20 0.48
SRC P12931 1/20 0.48
LCK P06239 1/20 0.47
MAPK1 P28482 1/20 0.46
ACHE P22303 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31554474 0.86 PDGFRB (0.52) PDGFRBPDGFRAPDPK1KDM1AIRAK1
SCHEMBL2063193 0.86 PDGFRB (0.52) PDGFRBPDGFRAPDPK1KDM1AIRAK1
SCHEMBL31554584 0.86 PDPK1 (0.54) PDGFRBPDGFRAPDPK1KDM1AIRAK1
SCHEMBL19645711 0.85 PDGFRB (0.53) PDGFRBPDGFRAPDPK1KDM1AIRAK1
SCHEMBL12335689 0.84 PDGFRB (0.50) PDGFRBPDGFRAPDPK1KDM1AIRAK1
SCHEMBL20143871 0.84 PDPK1 (0.46) PDPK1EGFRKDM4EKDRSRC
SCHEMBL15263519 0.83 SRC (0.61) PDGFRBPDGFRAEGFRKDRSRC
SCHEMBL5452461 0.83 EGFR (0.49) PDGFRBPDGFRAPDPK1KDM1AIRAK1
SCHEMBL1893875 0.83 SRC (0.61) PDGFRBPDGFRAEGFRKDRSRC
SCHEMBL5929650 0.83 EGFR (0.53) PDGFRBPDGFRAPDPK1KDM1AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393641-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF OXFORD FINANCE LLC 2021-12-23 US disclosed
US-9827248-B2 Therapeutic compounds and uses thereof KALA PHARMACEUTICALS, INC. (US) 2017-11-28 US disclosed
US-20070208164-A1 Methods of synthesizing radiolabeled 3-cyano[14C]quinolines WYETH (US) 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210393641-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF MUC1, CFTR, SLC26A4 PDGFRB 2819/4885PDGFRA 3408/4885PDPK1 3891/4885
US-20070208164-A1 Methods of synthesizing radiolabeled 3-cyano[14C]quinolines QPCT, RECQL, CBR3 PDGFRB 1994/4885PDGFRA 1687/4885PDPK1 3708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.